Ser718
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus®
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser718  -  STIM2 (human)

Site Information
APsVARIssIPHDLC   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 29577931

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 )
Disease tissue studied:
breast cancer ( 1 ) , lung cancer ( 1 ) , non-small cell lung cancer ( 1 )
Relevant cell line - cell type - tissue:
BT-20 (breast cell) ( 1 ) , BT-549 (breast cell) ( 1 ) , H2009 (pulmonary) ( 1 ) , H2077 (pulmonary) ( 1 ) , H2887 (pulmonary) ( 1 ) , H322 (pulmonary) ( 1 ) , H322M (pulmonary) ( 1 ) , HCC2279 (pulmonary) ( 1 ) , HOP62 (pulmonary) ( 1 ) , MDA-MB-231 (breast cell) ( 1 ) , MDA-MB-468 (breast cell) ( 1 ) , NCI-H157 (pulmonary) ( 1 ) , NCI-H1666 (pulmonary) ( 1 ) , NCI-H2172 (pulmonary) ( 1 ) , NCI-H520 (squamous) ( 1 ) , PC9 (pulmonary) ( 1 )

References 

1

Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68
22617229   Curated Info